Activation of calpain in myocardial infarction: An immunohistochemical study using a calpain antibody raised against active site histidine- containing peptide

Cardiovascular Pathology

Volumn 8, Issue 1, 1999, Pages 7-15

  Kunimatsu, Mitoshi ^a   Tada, Toyohiro ^a   Narita, Yasuko ^a   Ozaki, Yasuhiko ^a   Liu, Zhen Qui ^a   Shearer, Thomas R ^b   Sasaki, Makoto ^a  

^a NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

^b Oregon Hlth S   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALPAIN;

ARTICLE; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME ANALYSIS; HEART INFARCTION; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL;

ANIMALS; ANTIBODY FORMATION; ANTIBODY SPECIFICITY; BINDING SITES, ANTIBODY; BLOTTING, WESTERN; CALPAIN; CASEINS; ENZYME INHIBITORS; HISTIDINE; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; MYOCARDIAL INFARCTION; MYOCARDIUM; PEPTIDE FRAGMENTS; RABBITS; RATS;

EID: 0032942304     PISSN: 10548807     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1054-8807(98)00018-0     Document Type: Article

References (38)

1. 2+-dependent protease (calpain) and its high-molecular-weight endogenous inhibitor (calpastatin). Adv Enzyme Regul. 19:1980;407-424.
2. Murachi T. Calpain and calpastatin. Trends Biochem Sci. 8:1983;167-169.
3. Suzuki K, Ohno S, Emori Y, Imajoh S, Kawasaki H. Calcium-activated neutral protease (CANP) and its biological and medical implications. In: Prog Clin Biochem Med. Springer-Verlag, Berlin Heidelberg, 1987;5:46-65.
4. 2+ proteases (calpain I and calpain II) purified concurrently by the same method from rat kidney. J Biol Chem. 258:1983;8883-8889.
5. Inomata M., Nomoto M., Hayashi M., Nakamura M., Imahori K., Kawashima S. Comparison of low and high calcium requiring forms of the calcium-activated neutral protease (CANP) from rabbit skeletal muscle. J Biochem. 95:1984;1661-1670.
6. 2+-dependent protease. J Biol Chem. 259:1984;11627-11630.
7. Suzuki K., Saido T.C., Hirai S. Modulation of cellular signals by calpain. Ann New York Acad Sci. 674:1992;218-227.
8. Sato H., Hori M., Kitakaze M.et al. Reperfusion after brief ischemia disrupts the microtubule network in canine hearts. Circ Res. 72:1993;361-375.
9. Wencel-Drake J.D., Okita J.R., Annis D.S., Kunicki T.J. Activation of calpain I and hydrolysis of calpain substrates (actin-binding protein, glycoprotein Ib, and talin) are not a function of thrombin-induced platelet aggregation. Arterosc Thromb. 11:1991;882-891.
10. Kikuchi H., Imajoh-Ohmi S., Kanegasaki S. Novel antibodies specific for proteolyzed forms of protein kinase C. production of anti-peptide antibodies available for in situ analysis of intracellular limited proteolysis Biochim Biophys Acta. 1162:1993;171-176.
11. Yoshida K., Inui M., Harada K.et al. Reperfusion of rat heart after brief ischemia induces proteolysis of calspectin (nonerythroid spectrin or fodrin) by calpain. Circ Res. 77:1995;603-610.
12. Steenbergen C., Hill M.L., Jennings R.B. Cytoskeletal damage during myocardial ischemia. changes in vinculin immunofluorescence staining during total in vitro ischemia in canine heart Circ Res. 60:1987;478-486.
13. Toyo-Oka T., Shimizu T., Masaki T. Inhibition of proteolytic activity of calcium activated neutral protease by leupeptin and antipain. Biochem Biophys Res Commun. 82:1978;484-491.
14. Iizuka K., Kawaguchi H., Kitabatake A. Effects of thiol protease inhibitors on fodrin degradation during hypoxia in cultured myocytes. J Mol Cell Cardiol. 25:1993;1101-1109.
15. Toyo-oka T., Kamishiro T., Masaki M., Masaki T. Reduction of experimentally produced acute myocardial infarction size by a new synthetic inhibitor, NCO-700, against calcium-activated neutral protease. Jpn Heart J. 23:1982;829-834.
16. Toyo-oka T., Morita M., Shin W.S., Okai-Matsuo Y., Sugimoto T. Contribution of calcium-activated neutral protease to the degradation process of ischemic heart. Jpn Circ J. 55:1991;1124-1126.
17. 2-terminal processing of the large subunit J Biochem. 100:1986;633-642.
18. Sato Y., Mukai K., Watanabe S., Goto M., Shimosato Y. The AMeX method; a simplified technique of tissue processing and paraffin embedding with improved preservation of antigens for immunostaining. Am J Pathol. 125:1986;431-435.
19. David L.L., Shearer T.R., Shih M. Sequence analysis of lens beta-crystallins suggests involvement of calpain in cataract formation. J Biol Chem. 268:1993;19337-19340.
20. 2+-activated protease that partially degrades myofibrils. J Mol Cell Cardiol. 12:1980;533-551.
21. 2+-requiring protease, from human erythrocytes. purification and subunit structure Biomed Res. 4:1983;381-388.
22. Kunimatsu M., Higashiyama S., Sato K., Ohkubo I., Sasaki M. Calcium dependent cysteine proteinase is a precursor of a chemotactic factor for neutrophils. Biochem Biophys Res Commun. 164:1989;875-882.
23. Hudson D. Methodological implications of simultaneous solid-phase peptide synthesis. 1. Comparison of different coupling procedures. J Org Chem. 53:1988;617-624.
24. Hsu S., Raine L., Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques. a comparison between ABC and unlabeled antibody (PAP) procedures J Histochem Cytochem. 29:1981;577-580.
25. Welling G.W., Weijer W.J., Zee R., Welling-Wester S. Prediction of sequential antigenic regions in proteins. FEBS Lett. 188:1985;215-218.
26. Onizuka K., Kunimatsu M., Ozaki Y., Muramatsu K., Sasaki M., Nishino H. Distribution of μ-calpain proenzyme in the brain and other neural tissues in the rat. Brain Res. 697:1995;179-186.
27. Berti P.J., Storer A.C. Alignment/phylogeny of the papain superfamily of cysteine proteases. J Mol Biol. 246:1995;273-283.
28. Kent S.P., Diseker M. Early myocardial ischemia. Lab Invest. 4:1955;398-405.
29. Kent S.P. Intracellular plasma protein. a manifestation of cell injury in myocardial ischemia Nature. 210:1966;1279-1281.
30. Kent S.P. Diffusion of plasma proteins into cells. a manifestation of cell injury in human myocardial ischemia Am J Pathol. 50:1967;623-637.
31. Yeldandi A.V., Kaufman D.G., Reddy J.K. Cell injury and cellular adaptations. Damjanov I., Linder J. Anderson's Pathology (10th ed). 1996;357-386 Mosby, St. Louis, MO.
32. Raza-Ahmad A. Fibrinogen. a diagnostic market for early ischemia Biotech Histochem. 69:1994;268-272.
33. Robinson A. Inhibiting calpain, rescuing cells. Can Med Assoc J. 154:1996;193-195.
34. Silver B., Wever J., Fisher M. Medical therapy for ischemic stroke. Clin Neuropharm. 19:1996;101-128.
35. 2+-dependent neutral proteinase. Biochem Biophys Res Commun. 128:1985;331-338.
36. Pontremoli S., Salamino F., Sparatore B., Michetti M., Sacco O., Melloni E. Following association to the membrane, human erythrocyte procalpain is converted and released as fully active calpain. Biochim Biophys Acta. 831:1985;335-339.
37. Pontremoli S., Melloni E. Extralysosomal protein degradation. Ann Rev Biochem. 55:1986;455-481.
38. 2+-dependent neutral proteinase of human erythrocytes. Biochem Biophys Res Commun. 129:1985;389-395.